Lombard Odier Asset Management Europe Ltd Makes New $13.66 Million Investment in Boston Scientific Corporation $BSX

Lombard Odier Asset Management Europe Ltd bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 143,279 shares of the medical equipment provider’s stock, valued at approximately $13,662,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Renaissance Group LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth about $28,064,000. Rathbones Group PLC lifted its stake in Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after acquiring an additional 477,680 shares during the last quarter. Tounjian Advisory Partners LLC purchased a new position in Boston Scientific in the fourth quarter worth approximately $1,477,000. Waycross Partners LLC acquired a new position in Boston Scientific during the 4th quarter worth approximately $2,384,000. Finally, Kepler Cheuvreux Suisse SA acquired a new position in Boston Scientific during the 3rd quarter worth approximately $26,955,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director directly owned 13,878 shares in the company, valued at $776,057.76. The trade was a 19.35% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of analyst reports. Barclays reduced their price objective on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Stifel Nicolaus set a $75.00 target price on Boston Scientific in a report on Wednesday, May 27th. Oppenheimer set a $90.00 price target on Boston Scientific in a research note on Thursday, April 23rd. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $85.08.

Boston Scientific Stock Up 0.3%

BSX stock opened at $46.92 on Wednesday. Boston Scientific Corporation has a 52 week low of $45.99 and a 52 week high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market cap of $69.74 billion, a P/E ratio of 19.63, a P/E/G ratio of 0.89 and a beta of 0.56. The company’s 50-day moving average price is $55.74 and its 200 day moving average price is $74.02.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the company earned $0.75 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.